RVB-101 / ResVita Bio - LARVOL DELTA

ResVita Bio Receives NIH Grant to Develop Breakthrough Treatment for Severe Atopic Dermatitis (PRNewswire) - "ResVita Bio, a synthetic biology startup, announces that it has been awarded a $250,000 Phase 1 Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Disease (NIAID). This grant will be used to develop RVB-101, a genetically engineered cell therapy for the treatment for severe atopic dermatitis."

Financing • Atopic Dermatitis • Dermatitis • Immunology